Literature DB >> 18831934

Antibodies to carbonic anhydrase in patients with connective tissue diseases: relationship with lung involvement.

D Caccavo1, A Afeltra, A Rigon, M Vadacca, B B Zobel, D Zennaro, L Arcarese, F Buzzulini, N M Pellegrino, A Amoroso.   

Abstract

The aim of this study is to evaluate the presence of antibodies to carbonic anhydrase I and/or II (ACAI and ACAII) in patients affected by connective tissue diseases (CTD) and to investigate their association with lung involvement evaluated by High resolution CT scan (HRCT). Ninety-six patients affected by CTD were studied, i.e. 33 rheumatoid arthritis (RA), 8 psoriatic arthritis (PA), 8 ankylosing spondilitis (AS), 23 Systemic Lupus Erythematosus (SLE), 10 Sjogren Syndrome (SS), and 14 Systemic Sclerosis (SSc). ACA were detected by ELISA. The lung involvement was evaluated by means of a previously described HRCT score. According to a receiver operator characteristic curve, patients were divided into those with HRCT score > or = 10 and those with HRCT score < 10, where HRCT score > or = 10 was predictive of interstitial lung disease. ACAI and/or ACAII were detected in 30/96 patients (31.2%) (P < 0.0001 in comparison with controls). In particular, the prevalence of ACAI and/or ACAII was significantly higher in patients with RA (P = 0.002), PA (P < 0.0001), SLE (P = 0.0003) and SSc (P < 0.0001). A positive correlation was found between HRCT scores and CRP or ACAI levels (P = < 0.0001 and P = 0.004, respectively). Thirty-nine of 96 patients (40.6%) showed a HRCT score > or = 10 and both their CRP and ACAI levels were significantly higher when compared with patients showing a HRCT score less than 10 (P < 0.0006 and P = 0.0009, respectively). Moreover, C3 and C4 complement fractions inversely correlated with HRCT scores (P = 0.0004 and P < 0.0001, respectively) and lower values of C3 and C4 complement fractions were found in patients with HRCT score > or = 10 than in those with HRCT score less than 10 (P = 0.014 and P = 0.007, respectively). Due to the lower levels of complement fractions detected in patients with HRCT score > or = 10, a possible immune-complex-mediated pathogenic mechanism of lung involvement could be suggested.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18831934     DOI: 10.1177/039463200802100320

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  6 in total

Review 1.  Sjögren syndrome: advances in the pathogenesis from animal models.

Authors:  J A Chiorini; D Cihakova; C E Ouellette; P Caturegli
Journal:  J Autoimmun       Date:  2009-10-02       Impact factor: 7.094

Review 2.  Mouse Models of Primary Sjogren's Syndrome.

Authors:  Young-Seok Park; Adrienne E Gauna; Seunghee Cha
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 3.  Current concepts: mouse models of Sjögren's syndrome.

Authors:  Tegan N Lavoie; Byung Ha Lee; Cuong Q Nguyen
Journal:  J Biomed Biotechnol       Date:  2010-12-30

4.  The local complement activation on vascular bed of patients with systemic sclerosis: a hypothesis-generating study.

Authors:  Cinzia Scambi; Sara Ugolini; T Sakari Jokiranta; Lucia De Franceschi; Oscar Bortolami; Valentina La Verde; Patrizia Guarini; Paola Caramaschi; Viviana Ravagnani; Guido Martignoni; Chiara Colato; Serena Pedron; Fabio Benedetti; Marco Sorio; Fabio Poli; Domenico Biasi
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

5.  Sera of patients with spontaneous tumour regression and elevated anti-CA I autoantibodies change the gene expression of ECM proteins.

Authors:  Jan Lakota; Radivojka Vulic; Maria Dubrovcakova; Silvia Tyciakova
Journal:  J Cell Mol Med       Date:  2016-10-05       Impact factor: 5.310

Review 6.  Recent Advances in Mouse Models of Sjögren's Syndrome.

Authors:  Yunzhen Gao; Yan Chen; Zhongjian Zhang; Xinhua Yu; Junfeng Zheng
Journal:  Front Immunol       Date:  2020-06-30       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.